Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE43258 E1
Publication typeGrant
Application numberUS 12/966,674
Publication date20 Mar 2012
Filing date13 Dec 2010
Priority date29 Apr 2003
Fee statusPaid
Publication number12966674, 966674, US RE43258 E1, US RE43258E1, US-E1-RE43258, USRE43258 E1, USRE43258E1
InventorsKatherine G. Truncale, Moon Hae Sunwoo, Arthur A. Gertzman, William W. Tomford
Original AssigneeMusculoskeletal Transplant Foundation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Glue for cartilage repair
US RE43258 E1
Abstract
The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers with allogenic chondrocytes or bone marrow cells in an amount exceeding the natural occurrence of same in hyaline cartilage and adding a cell growth additive.
Images(1)
Previous page
Next page
Claims(110)
What we claim is:
1. A sterile allograft cartilage defect implant material for use in human beings comprising milled allograft cartilage pieces sized less than 1 mm and lyophilized so that their water content ranges from about 0.1% to about 8.0% in a bioabsorbable carrier.
2. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.
3. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.
4. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said carrier is sodium hyaluronate and its derivatives.
5. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said implant material includes a protein glue.
6. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said implant material includes the addition of autologous chondrocytes to achieve a concentration exceeding the concentration of chondrocytes naturally occurring in the patient.
7. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage is hyaline cartilage.
8. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage is fibrosus cartilage.
9. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage is hyaline and fibrosus cartilage.
10. A sterile allograft cartilage defect implant material claimed in claim 1 including an additive to said implant material consisting of one or more of a group consisting of growth factors, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, human demineralized bone matrix, and insulin.
11. A sterile cartilage repair material as claimed in claim 10 wherein said growth factors are one or more of a group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF.
12. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said carrier comprises one or more bioabsorbable carriers taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers.
13. A sterile cartilage defect implant material comprising milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and allogenic chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage.
14. A sterile cartilage defect implant material as claimed in claim 13 wherein said allograft articular cartilage is hyaline cartilage.
15. A sterile allograft cartilage defect implant material as claimed in claim 13 wherein said milled cartilage is fibrous cartilage.
16. A sterile allograft cartilage defect implant material as claimed in claim 13 wherein said milled cartilage is hyaline and fibrous cartilage.
17. A sterile cartilage repair material as claimed in claim 13 wherein said implant material includes an additive consisting of one or more of a group consisting of growth factors, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, demineralized bone matrix, and insulin.
18. A sterile cartilage repair material as claimed in claim 17 wherein said growth factors are one or more of a group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF.
19. A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.
20. A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.
21. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and autologous bone marrow cells in an amount exceeding the natural occurrence of same in a patient being treated.
22. A sterile cartilage defect repair material as claimed in claim 21 including an additive in said implant material which consists of one or more of a group consisting of growth factors, human allogenic cells, autologous chondrocytes, demineralized bone matrix, and insulin.
23. A sterile cartilage repair material as claimed in claim 22 wherein said growth factors are one or more of a group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF.
24. A sterile cartilage defect repair material as claimed in claim 21 wherein said bioabsorbable carrier consists of sodium hyaluronate, hyaluronic acid and its derivatives.
25. A sterile cartilage defect material as claimed in claim 21 wherein said lyophilized cartilage pieces have a water content ranging from about 0.1% to 8.0%.
26. A sterile cartilage defect implant material as claimed in claim 21 wherein said allograft articular cartilage is hyaline cartilage.
27. A sterile allograft cartilage defect implant material as claimed in claim 21 wherein said milled cartilage is fibrous cartilage.
28. A sterile allograft cartilage defect implant material as claimed in claim 21 wherein said milled cartilage is hyaline and fibrous cartilage.
29. A sterile cartilage defect implant material as claimed in claim 21 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.
30. A sterile cartilage defect implant material as claimed in claim 21 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.
31. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and autologous stem cells in an amount exceeding the natural occurrence of same in a patient being treated.
32. A method of placing a cartilage defect material in a cartilage defect, said cartilage defect material comprising milled allograft articular cartilage which has been lyophilized and mixed in a bioabsorbable carrier comprising the steps of:
(a) cutting a patient's tissue at a site of a cartilage defect to remove a diseased area of cartilage;
(b) adding autologous cells to said mixture of milled allograft cartilage in a bioabsorbable carrier;
(c) placing a mixture of milled allograft cartilage with added autologous cells in a bioabsorbable carrier in the cartilage defect area where cartilage has been removed; and
(d) placing a cover over the mixture of milled allograft cartilage in a bioabsorbable carrier to contain the mixture in cartilage defect site for a predetermined period of time.
33. The method of claim 32 wherein growth factors are added to said mixture.
34. The method of claim 32 wherein said autologous cells are chondrocytes.
35. The method of claim 32 wherein said autologous cells are bone marrow cells.
36. The method of claim 32 wherein said autologous cells are stem cells.
37. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives and chitosan and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage, wherein said milled cartilage ranges from about 25% to about 50% by weight and said bioabsorbable carrier ranges from about 75% to about 50% by weight.
38. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of gelatin, collagen and alginate and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage, wherein said milled cartilage ranges from about 25% to about 50% by weight and said bioabsorbable carrier ranges from about 75% to about 50% by weight.
39. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of buffered PBS, Dextran or polymers and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage, wherein said milled cartilage ranges from about 25% to about 50% by weight and said bioabsorbable carrier ranges from about 75% to about 50% by weight.
40. A cartilage defect repair material for use in human beings, comprising a mixture having a bioabsorbable carrier and freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said mixture being in the form of a gel.
41. A cartilage defect repair material for use in human beings, comprising a mixture having a bioabsorbable carrier and freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said mixture being in the form of a paste, and said cartilage pieces being present in said mixture in an amount within the range of from about 25% to about 50% by weight.
42. A cartilage defect repair material for use in human beings, comprising a mixture having a bioabsorbable carrier and freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said mixture being in the form of one of a paste and a gel, and said cartilage pieces being present in said mixture in an amount within the range of from about 15% to about 50% by weight.
43. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed from allograft cartilage having a reduced water content.
44. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed from allograft cartilage having a reduced water content within the range of about 0.1% to about 8.0% by weight.
45. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed from allograft cartilage that has been lyophilized so as to reduce its water content to an amount within the range of about 0.1% to about 8.0% by weight.
46. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said size is in the range of 0.01 mm to 1.0 mm.
47. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces are allograft articular cartilage pieces.
48. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces include hyaline cartilage.
49. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces lack cell viability.
50. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage defect repair material is free of added chondrocytes.
51. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage defect repair material is free of bone pieces.
52. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said mixture is formed for implantation directly in a defect site.
53. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces have an ability to promote the growth of new articular cartilage in a cartilage defect.
54. A cartilage defect repair material as claimed in claim 40, wherein said allograft cartilage pieces are present in said mixture in an amount in the range of from about 15% to about 30% by weight and said bioabsorbable carrier is present in said mixture in an amount in the range of from about 70% to about 85% by weight.
55. A cartilage defect repair material as claimed in claim 41, wherein said bioabsorbable carrier is present in said mixture at an amount in the range of from about 50% to about 75% by weight.
56. A cartilage defect repair material as claimed in claim 42, wherein said bioabsorbable carrier is present in said mixture in an amount within the range of from about 50% to about 85% by weight.
57. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.
58. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces are formed by milling frozen allograft articular cartilage.
59. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said cartilage pieces are formed by freeze-milling allograft cartilage subsequent to reducing the water content of the allograft cartilage.
60. A cartilage defect repair material as claimed in any one of claims 40, 41 and 42, wherein said allograft cartilage pieces are formed by a process including the steps of harvesting a donor tissue consisting essentially of articular cartilage, reducing the water content of said donor tissue, and freeze-milling said donor tissue.
61. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, said mixture including a bioabsorbable carrier, and said allograft cartilage pieces including fibrocartilage.
62. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, said mixture including a bioabsorbable carrier, and said allograft cartilage pieces including hyaline cartilage and fibrocartilage.
63. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and a protein glue.
64. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier selected from the group consisting of sodium hyaluronate, hyaluronic acid, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, and polymers.
65. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier selected from the group consisting of sodium hyaluronate and hyaluronic acid.
66. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and an additive selected from the group consisting of a growth factor, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, human demineralized bone matrix, insulin, insulin-like growth factor-1, interleukin-1 receptor agonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog, and parathyroid hormone-related peptide.
67. A cartilage defect repair material as claimed in claim 66, wherein said growth factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.
68. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and autologous chondrocytes at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.
69. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and allogenic chondrocytes at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.
70. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and autologous bone marrow cells at a concentration greater than the concentration of bone marrow cells that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.
71. A cartilage defect repair material for use in human beings, comprising freeze-milled allograft cartilage pieces having a size not greater than 1 mm, said cartilage pieces being included in a mixture, and said mixture including a bioabsorbable carrier and autologous stem cells at a concentration greater than the concentration of stem cells that are naturally present in hyaline cartilage of a human being having an age in the range of 20 years to 55 years.
72. A method of repairing a cartilage defect in a human being, comprising the step of placing in a defect site freeze-milled allograft cartilage pieces having a size not greater than 1 mm.
73. A method as claimed in claim 72, wherein the cartilage pieces have a water content within the range of about 0.1% to about 8.0% by weight prior to their placement in the defect site.
74. A method as claimed in claim 72, wherein the cartilage pieces are formed from allograft cartilage having a reduced water content.
75. A method as claimed in claim 72, wherein the cartilage pieces are formed from allograft cartilage which has been dried so as to reduce its water content to an amount within the range of about 0.1% to about 8.0% by weight.
76. A method as claimed in claim 72, wherein the size of the cartilage pieces ranges from 0.01 mm to 1.0 mm.
77. A method as claimed in claim 72, wherein the cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.
78. A method as claimed in claim 72, wherein the cartilage pieces are formed by freeze-milling allograft cartilage subsequent to reducing the water content of the allograft cartilage.
79. A method as claimed in claim 72, wherein the defect site includes a defect in articular cartilage.
80. A method as claimed in claim 72, wherein the freeze-milled allograft cartilage pieces consist essentially of articular cartilage.
81. A method as claimed in claim 72, wherein the freeze-milled allograft cartilage pieces lack cell viability.
82. A method as claimed in claim 72, comprising the further steps of harvesting a donor tissue consisting essentially of articular cartilage, reducing the water content of said donor tissue, and freeze-milling said donor tissue.
83. A method as claimed in claim 72, comprising the further step of forming the freeze-milled allograft cartilage pieces by a process including the step of milling frozen allograft articular cartilage.
84. A method as claimed in claim 72, wherein the allograft cartilage pieces are free of added chondrocytes.
85. A method as claimed in claim 79, wherein the cartilage pieces have an ability to promote the growth of new articular cartilage in the articular cartilage defect.
86. A method as claimed in claim 72, comprising the further steps of cutting a patient's tissue to remove a diseased area of cartilage from the defect site; and placing a cover over the allograft cartilage pieces so as to contain the allograft cartilage pieces in the defect site.
87. A method as claimed in claim 86, further comprising the step of adding cells to the defect site.
88. A method as claimed in claim 87, wherein the cells are selected from the group consisting of chondrocytes, bone marrow cells and stem cells.
89. A method as claimed in claim 72, wherein the cartilage pieces are included in a mixture, the mixture including a bioabsorbable carrier.
90. A method as claimed in claim 89, wherein said placing step includes the step of placing the mixture in the defect site, said method comprising the further steps of cutting a patient's tissue to remove a diseased area of cartilage from the defect site; and placing a cover over the mixture so as to contain the mixture in the defect site.
91. A method as claimed in claim 90, further comprising the step of adding cells to the defect site.
92. A method as claimed in claim 91, wherein the cells are selected from the group consisting of chondrocytes, bone marrow cells and stem cells.
93. A method as claimed in claim 90, comprising the further step of adding a growth factor to the mixture.
94. A method as claimed in claim 90, further comprising the step of fixing the mixture in the cartilage defect site with an organic glue.
95. A method as claimed in claim 90, further comprising the step of keeping the cover over the mixture for a predetermined period of time that is sufficient to promote cartilage growth at the defect site.
96. A method as claimed in claim 90, wherein the cover is selected from the group consisting of a periosteal flap and a perichondrial flap.
97. A method for making a cartilage defect repair material for use in human beings from allograft cartilage, said method comprising the steps of freeze-milling the allograft cartilage so as to form freeze-milled allograft cartilage pieces having a size not greater than 1 mm; and mixing the freeze-mill cartilage pieces with a bioabsorbable carrier to form a mixture in the form of a gel.
98. A method for making a cartilage defect repair material for use in human beings from allograft cartilage, said method comprising the steps of freeze-milling the allograft cartilage so as to form freeze-milled allograft cartilage pieces having a size not greater than 1 mm; and mixing the freeze-mill cartilage pieces with a bioabsorbable carrier to form a mixture in the form of a paste, the freeze-milled cartilage pieces being present in the mixture in an amount within the range of from about 25% to about 50% by weight.
99. A method for making a cartilage defect repair material for use in human beings from allograft cartilage, said method comprising the steps of freeze-milling the allograft cartilage so as to form freeze-milled allograft cartilage pieces having a size not greater than 1 mm; and mixing the freeze-mill cartilage pieces with a bioabsorbable carrier to form a mixture in the form of one of a paste and a gel, the freeze-milled cartilage pieces being present in the mixture in an amount within the range of from about 15% to about 50% by weight.
100. A method as claimed in any one of claims 97, 98 and 99, comprising the further step of reducing the water content of the allograft cartilage.
101. A method as claimed in claim 100, wherein said reducing step is performed so as to reduce the water content of the allograft cartilage to an amount within the range of about 0.1% to about 8.0% by weight.
102. A method as claimed in claim 100, wherein said reducing step is performed prior to said freeze-milling step.
103. A method as claimed in claim 100, wherein said reducing step includes the step of lyophilizing the allograft cartilage.
104. A method as claimed in any one of claims 97, 98 and 99, wherein said freeze-milling step includes the step of freezing the cartilage and the step of milling the frozen cartilage.
105. A method as claimed in any one of claims 97, 98 and 99, wherein said freeze-milling step is performed by milling the cartilage in a frozen state.
106. A method as claimed in any one of claims 97, 98 and 99, wherein the freeze-milled cartilage pieces have a water content within the range of about 0.1% to about 8.0% by weight.
107. A method as claimed in any one of claims 97, 98 and 99, wherein the size of the freeze-milled cartilage pieces ranges from 0.01 mm to 1.0 mm.
108. A method as claimed in any one of claims 97, 98 and 99, wherein the allograft cartilage includes allograft articular cartilage.
109. A method as claimed in any one of claims 97, 98 and 99, comprising the further step of harvesting the allograft cartilage from a donor tissue consisting essentially of articular cartilage.
110. A method as claimed in any one of claims 97, 41 and 42, wherein the mixture is formed for implantation directly in a defect site.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

More than one reissue application has been filed for the reissue of U.S. Pat. No. 7,067,123, issued Jun. 27, 2006, said reissue applications being U.S. application Ser. No. Re. 12/147,042, filed Jun. 26, 2008, now U.S. Pat. No. Re. 42,208, and the present application, which is a continuation reissue application of U.S. application Ser. No. Re. 12/147,042.

RELATED APPLICATIONS

There is no related application.

1. Field of Invention

The present invention is generally directed toward an implant and is more specifically directed toward a paste or gel implant material for a cartilage defect.

2. Background of the Invention

Articular cartilage injury and degeneration present medical problems to the general population which are addressed by orthopedic surgeons. Every year in the United States, over 500,000 arthroplastic or joint repair procedures are performed. These include approximately 125,000 total hip and 150,000 total knee arthroplastics and over 41,000 open arthroscopic procedures to repair cartilaginous defects of the knee.

In the knee joint, the articular cartilage tissue forms a lining which faces the joint cavity on one side and is linked to the subchondral bone plate by a narrow layer of calcified cartilage tissue on the other. Articular cartilage (hyaline cartilage) consists primarily of extracellular matrix with a sparse population of chondrocytes distributed throughout the tissue. Articular cartilage is composed of chondrocytes, type II collagen fibril network, proteoglycans and water. Active chondrocytes are unique in that they have a relatively low turnover rate and are sparsely distributed within the surrounding matrix. The collagens give the tissue its form and tensile strength and the interaction of proteoglycans with water give the tissue its stiffniess to compression, resilience and durability. The hyaline cartilage provides a low friction bearing surface over the bony parts of the joint. If the lining becomes worn or damaged resulting in lesions, joint movement may be painful or severely restricted. Whereas damaged bone typically can regenerate successfully, hyaline cartilage regeneration is quite limited because of it's limited regenerative and reparative abilities.

Articular cartilage lesions generally do not heal, or heal only partially under certain biological conditions due to the lack of nerves, blood vessels and a lymphatic system. The limited reparative capabilities of hyaline cartilage usually results in the generation of repair tissue that lacks the structure and biomechanical properties of normal cartilage. Generally, the healing of the defect results in a fibrocartilaginous repair tissue that lacks the structure and biomedical properties of hyaline cartilage and degrades over the course of time. Articular cartilage lesions are frequently associated with disability and with symptoms such as joint pain, locking phenomena and reduced or disturbed function. These lesions are difficult to treat because of the distinctive structure and function of hyaline cartilage. Such lesions are believed to progress to severe forms of osteoarthritis. Osteoarthritis is the leading cause of disability and impairment in middle-aged and older individuals, entailing significant economic, social and psychological costs. Each year, osteoarthritis accounts for as many as 39 million physician visits and more than 500,000 hospitalizations. By the year 2020, arthritis is expected to affect almost 60 million persons in the United States and to limit the activity of 11.6 million persons.

There are many current therapeutic methods being used. None of these therapies has resulted in the successful regeneration of hyaline-like tissue that withstands normal joint loading and activity over prolonged periods. Currently, the techniques most widely utilized clinically for cartilage defects and degeneration are not articular cartilage substitution procedures, but rather lavage, arthroscopic debridement, and repair stimulation. The direct transplantation of cells or tissue into a defect and the replacement of the defect with biologic or synthetic substitutions presently accounts for only a small percentage of surgical interventions. The optimum surgical goal is to replace the defects with cartilage-like substitutes so as to provide pain relief, reduce effusions and inflammation, restore function, reduce disability and postpone or alleviate the need for prosthetic replacement.

Lavage and arthroscopic debridement involve irrigation of the joint with solutions of sodium chloride, Ringer or Ringer and lactate. The temporary pain relief is believed to result from removing degenerative cartilage debris, proteolytic enzymes and inflammatory mediators. These techniques provide temporary pain relief, but have little or no potential for further healing.

Repair stimulation is conducted by means of drilling, abrasion arthroplasty or microfracture. Penetration into the subchondral bone induces bleeding and fibrin clot formation which promotes initial repair, however, the tissue formed is fibrous in nature and not durable. Pain relief is temporary as the tissue exhibits degeneration, loss of resilience, stiffness and wear characteristics over time.

The periosteum and perichondrium have been shown to contain mesenchymal progenitor cells capable of differentiation and proliferation. They have been used as grafts in both animal and human models to repair articular defects. Few patients over 40 years of age have obtained good clinical results, which most likely reflects the decreasing population of osteochondral progenitor cells with increasing age. There have also been problems with adhesion and stability of the grafts, which result in their displacement or loss from the repair site.

Transplantation of cells grown in culture provides another method of introducing a new cell population into chondral and osteochondral defects. Carticel® is a commercial process to culture a patient's own cartilage cells for use in the repair of cartilage defects in the femoral condyle marketed by Genzyme Biosurgery in the United States and Europe. The procedure uses arthroscopy to take a biopsy from a healthy, less loaded area of articular cartilage. Enzymatic digestion of the harvested tissue releases the cells that are sent to a laboratory where they are grown for a period ranging from 2-5 weeks. Once cultivated, the cells are injected during a more open and extensive knee procedure into areas of defective cartilage where it is hoped that they will facilitate the repair of damaged tissue. An autologous periosteal flap with cambium layer is used to seal the transplanted cells in place and act as a mechanical barrier. Fibrin glue is used to seal the edges of the flap. This technique preserves the subchondral bone plate and has reported a high success rate. Proponents of this procedure report that it produces satisfactory results, including the ability to return to demanding physical activities, in more than 90% of patients and that biopsy specimens of the tissue in the graft sites show hyaline-like cartilage repair. More work is needed to assess the function and durability of the new tissue and determine whether it improves joint function and delays or prevents joint degeneration. As with the perichondrial graft, patient/donor age may compromise the success of this procedure as chondrocyte population decreases with increasing age. Disadvantages to this procedure include the need for two separate surgical procedures, potential damage to surrounding cartilage when the periosteal patch is sutured in place, the requirement of demanding microsurgical techniques, and the expensive cost of the procedure which is currently not covered by insurance.

Osteochondral transplantation or mosaicplasty involves excising all injured or unstable tissue from the articular defect and creating cylindrical holes in the base of the defect and underlying bone. These holes are filled with autologous cylindrical plugs of healthy cartilage and bone in a mosaic fashion. The osteochondral plugs are harvested from a lower weight-bearing area of lesser importance in the same joint. This technique, shown in Prior Art FIG. 2, can be performed as arthroscopic or open procedures. Reports of results of osteochondral plug autografts in a small number of patients indicate that they decrease pain and improve joint function, however, long-term results have not been reported. Factors that can compromise the results include donor site morbidity, effects of joint incongruity on the opposing surface of the donor site, damage to the chondrocytes at the articular margins of the donor and recipient sites during preparation and implantation, and collapse or settling of the graft over time. The limited availability of sites for harvest of osteochondral autografts restricts the use of this approach to treatment of relatively small articular defects and the healing of the chondral portion of the autograft to the adjacent articular cartilage remains a concern.

Transplantation of large allografts of bone and overlying articular cartilage is another treatment option that involves a greater area than is suitable for autologous cylindrical plugs, as well as for a non-contained defect. The advantages of osteochondral allografts are the potential to restore the anatomic contour of the joint, lack of morbidity related to graft harvesting, greater availability than autografts and the ability to prepare allografts in any size to reconstruct large defects. Clinical experience with fresh and frozen osteochondral allografts shows that these grafts can decrease joint pain, and that the osseous portion of an allograft can heal to the host bone and the chondral portion can function as an articular surface. Drawbacks associated with this methodology in the clinical situation include the scarcity of fresh donor material and problems connected with the handling and storage of frozen tissue. Fresh allografts carry the risk of immune response or disease transmission. Musculoskeletal Transplant Foundation (MTF) has preserved fresh allografts in a media that maintains a cell viability of 50% for 35 days for use as implants. Frozen allografts lack cell viability and have shown a decreased amount of proteoglycan content which contribute to deterioration of the tissue.

A number of patents in the prior art show the use of bone putty, pastes or gels to fill bone defects. U.S. Pat. No. 5,290,558 issued Mar. 1, 1994 discloses a flowable demineralized bone powder composition using an osteogenic bone powder with large particle size ranging from about 0.1 to about 1.2 cm. mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.

A bone gel is disclosed in the U.S. Pat. No. 5,073,373 issued Dec. 17, 1991. Bone lamellae in the shape of threads or filaments retaining low molecular weight glycerol carrier are disclosed in U.S. Pat. Nos. 5,314,476 issued May 24, 1994 and 5,507,813 issued Apr. 16, 1996 and the tissue forms described in these patents are known commercially as the GRAFTON® Putty and Flex, respectively.

U.S. Pat. No. 5,356,629 issued Oct. 18, 1994 discloses making a rigid gel in the nature of a bone cement to fill defects in bone by mixing biocompatible particles, preferably polymethylmethacrylate coated with polyhydroxyethylmethacrylate in a matrix selected from a group which lists hyaluronic acid to obtain a molded semi-solid mass which can be suitably worked for implantation into bone. The hyaluronic acid can also be utilized in monomeric form or in polymeric form preferably having a molecular weight not greater than about one million Daltons. It is noted that the nonbioabsorbable material which can be used to form the biocompatible particles can be derived from xenograft bone, homologous bone, autogenous bone as well as other materials. The bioactive substance can also be an osteogenic agent such as demineralized bone powder, morselized cancellous bone, aspirated bone marrow and other autogenous bone sources. The average size of the particles employed is preferably about 0.1 to about 3.0 mm, more preferably about 0.2 to about 1.5 mm, and most preferably about 0.3 to about 1.0 mm. It is inferentially mentioned but not taught that particles having average sizes of about 7,000 to 8,000 microns, or even as small as about 100 to 700 microns can be used.

U.S. Pat. No. 4,172,128 issued Oct. 23, 1979 discloses a demineralized bone material mixed with a carrier to reconstruct tooth or bone material by adding a mucopolysaccharide to a mineralized bone colloidal material. The composition is formed from a demineralized coarsely ground bone material, which may be derived from human bones and teeth, dissolved in a solvent forming a colloidal solution to which is added a physiologically inert polyhydroxy compound such as mucopolysaccharide or polyuronic acid in an amount which causes orientation when hydrogen ions or polyvalent metal ions are added to form a gel. The gel will be flowable at elevated temperatures above 35° C. and will solidify when brought down to body temperature. Example 25 of the patent notes that mucopolysaccharides produce pronounced ionotropic effects and that hyaluronic acid is particularly responsible for spatial cross-linking.

U.S. Pat. No. 6,030,635 issued Feb. 29, 2000 and U.S. Pat. No. 6,437,018 issued Aug. 20, 2002 are directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which utilize a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier which contains a sodium phosphate saline buffer.

The use of implants for cartilage defects is much more limited. Aside from the fresh allograft implants and autologous implants, U.S. Pat. No. 6,110,209 issued Nov. 5, 1998 shows the use an autologous articular cartilage cancerous bone paste to fill arthritic defects. The surgical technique is arthroscopic and includes debriding (shaving away loose or fragmented articular cartilage), followed by morselizing the base of the arthritic defect with an awl until bleeding occurs. An osteochondral graft is then harvested from the inner rim of the intercondylar notch using a trephine. The graft is then morselized in a bone graft crusher, mixing the articular cartilage with the cancellous bone. The paste is then pushed into the defect and secured by the adhesive properties of the bleeding bone. The paste can also be mixed with a cartilage stimulating factor, a plurality of cells, or a biological glue. All patients are kept non-weight bearing for four weeks and used a continuous passive motion machine for six hours each night. Histologic appearance of the biopsies have mainly shown a mixture of fibrocartilage with hyaline cartilage. Concerns associated with this method are harvest site morbidity and availability, similar to the mosaicplasty method.

SUMMARY OF THE INVENTION

A cartilage implant material in paste or gel form for repairing articular cartilage defects is composed of milled allograft cartilage pieces in a bioabsorbable carrier. Autologous chondrocyte in an amount exceeding the number naturally occurring in hyaline cartilage for a mature adult between 20 and 55 years of age may also be applied to the matrix. Additives may be applied to the mixture in order to increase chondrocyte migration and proliferation. The implant material can support the addition of a variety of chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic or autologous bone marrow cells, stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, transforming growth factor-B, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide or bioactive glue.

The implant material is placed in the lesion area and may be sealed with a periosteum cap.

It is an object of the invention to provide an allograft implant material for joints which provides pain relief, restores normal function and will postpone or alleviate the need for prosthetic replacement.

It is also an object of the invention to provide a cartilage repair implant material which is easily placed in a defect area by the surgeon using an arthroscopic, minimally invasive technique.

It is further an object of the invention to provide an allograft implant material procedure which is applicable for both partial and full thickness lesions.

It is yet another object of the invention to provide an allograft implant material which facilitates growth of hyaline cartilage.

It is an additional object of the invention to provide implant paste and gel material formulations that satisfy surgical requirements and are made from donated human available allograft tissue, some of which would otherwise be considered waste and thrown away.

These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the anatomy of a knee joint with a lesion;

FIG. 2 shows a schematic mosaicplasty as known in the prior art; and

FIG. 3 shows a schematic perspective view of cartilage defect material placed in a defect site with an exploded periosteum cap.

DESCRIPTION OF THE INVENTION

The terms “tissue” is used in the general sense herein to mean any transplantable or implantable tissue, the survivability of which is improved by the methods described herein upon implantation. In particular, the overall durability and longevity of the implant are improved, and host-immune system mediated responses, are substantially eliminated.

The terms “transplant” and “implant” are used interchangably to refer to tissue, material or cells (xenogeneic or allogeneic) which may be introduced into the body of a patient to replace or supplement the structure or function of the endogenous tissue.

The terms “autologous” and “autograft” refer to tissue or cells which originate with or are derived from the recipient, whereas the terms “allogeneic” and “allograft” refer to cells and tissue which originate with or are derived from a donor of the same species as the recipient. The terms “xenogeneic” and “xenograft” refer to cells or tissue which originates with or is derived from a species other than that of the recipient.

The term “gel” refers to a mixture of minced or milled pretreated allograft cartilage in a biocomposite carrier having a viscosity which is less than and is less rigid than a mixture of minced or milled pretreated allograft cartilage in a biocompatible carrier referred to by the terms “putty” or “paste” and contains less cartilage by weight than putty or paste.

The present invention is directed towards a cartilage repair material and method of treatment. The preferred embodiment and best mode of the invention is shown in FIG. 3. In the production of the invention, allograft hyaline cartilage is lyophilized reducing its water content and milled for ease in application.

After washes with sterile de-ionized (DI) water, the cartilage material was frozen at −20° to −100° C. preferably −70° C. and lyophilized to reduce the water content within the range of about 0.1% to about 8.0%. The cartilage is frozen with liquid nitrogen and ground into particles.

A lesion or defect is removed by cutting a bore 50 or trimming a lesion in the implant area 100 and filling the bore 50 or lesion area with a milled cartilage mixture 20 of paste or gel consisting together with a biological carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers and one or more additives namely chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic cells, human allogenic or autologous bone marrow cells, human allogenic or autologous stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide.

Suitable organic glue material can be used to keep the viscous cartilage mixture 20 fixed in place in the implant area or to affix a periosteal cap 30 in place over the surrounding hyaline cartilage area 100. Suitable organic glue material can be found commercially, such as for example; TISSEEL® or TISSUCOL.®) (fibrin based adhesive; Immuno AG, Austria), Adhesive Protein (Sigma Chemical, USA), and Dow Corning Medical Adhesive B (Dow Corning, USA).

EXAMPLE 1

A matrix of minced cartilage putty consisting of minced or milled allograft articular cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% with a cartilage content ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) (molecular weight ranging from 7.0×105 to 1.2×106) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers, the carrier ranging from 75% to 50% by weight. The cartilage is milled to a size ranging from 0.01 mm to 1 mm. In gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage when milled is less than or equal to 1 mm dry in the previously stated range. The cartilage pieces can be processed to varying particle sizes and the HA or other carrier can have different viscosities depending on the desired consistency of the putty or paste. This cartilage matrix can be deposited into the cartilage defect arthroscopically and fit into the defect where it is held in place by it's own viscosity, mixed with fibrin glue or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first two matrices, this matrix can support the previously mentioned chondrogenic factors.

EXAMPLE 2

A matrix of minced cartilage putty consisting of minced or milled allograft cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) (7.0×105 to 1.2×106) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers ranging from 75% to 50% by weight. In a gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.01% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage is less than or equal to 1 mm dry ranging from 0.01 mm to 1 mm. The cartilage pieces can be processed to varying particle sizes and the HA or carrier can have different viscosities depending on the desired consistency of the putty or paste. Autologous or allogenic cells which have been grown outside the patient are inserted by syringe into the matrix before, during or after deposit of the cartilage matrix into the defect area. Such cells include allogenic or autologous bone marrow cells, stem cells and chondrocyte cells. The cellular density of the cells preferably ranges from about 1×108 to 5×108 or from about 100 million to about 500 million cells per cc of putty or gel mixture. This composite material can be injected into the cartilage defect arthroscopically and fit into the defect where it is held in place by it's own viscosity, or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first matrix, this matrix can support the previously mentioned chondrogenic factors.

The operation of placing the cartilage composition in a cartilage defect, comprises (a) cutting a patient's tissue at a site of a cartilage defect to remove the diseased area of cartilage; (b) placing a mixture of milled allograft cartilage in a bioabsorbable carrier in the defect area; and (c) placing a periosteal cover over the mixture of the inserted milled allograft cartilage in a bioabsorbable carrier to contain the mixture in the defect area for a predetermined period of time to promote cartilage growth at the defect site. Alternate steps include the addition of growth factors, chondrocytes, bone marrow cells and stem cells.

The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US340019926 Feb 19653 Sep 1968Leslie L. BalassaWound-healing cartilage powder
US347685517 Jan 19684 Nov 1969Balassa Leslie LSterilizing and enhancing activity of a finely divided cartilage powder
US347814617 Jan 196811 Nov 1969Balassa Leslie LWound-healing cartilage powder extracting process
US35515602 Oct 196729 Dec 1970Heinrich F ThieleProcess of reconstructing tendons,cartilage,nerve sheaths,and products
US377243211 Jan 197113 Nov 1973Lescarden LtdCartilage compositions for dental use
US38677285 Apr 197325 Feb 1975Cutter LabProsthesis for spinal repair
US396690810 Jul 197529 Jun 1976Lescarden Ltd.Method of treating degenerative joint afflictions
US406008115 Jul 197529 Nov 1977Massachusetts Institute Of TechnologyMultilayer membrane useful as synthetic skin
US417212812 May 197723 Oct 1979Erhard ThieleProcess of degrading and regenerating bone and tooth material and products
US42018456 Feb 19786 May 1980Monsanto CompanyCell culture reactor
US429610030 Jun 198020 Oct 1981Franco Wayne PAdministering fibroblast growth factor to increase blood flow in ischemic area
US437834718 Jun 198129 Mar 1983Franco Wayne PComposition for treating the heart for myocardial infarction
US439437021 Sep 198119 Jul 1983Jefferies Steven RBone graft material for osseous defects and method of making same
US440083310 Jun 198130 Aug 1983Kurland Kenneth ZMeans and method of implanting bioprosthetics
US444265525 Jun 198217 Apr 1984Serapharm Michael StroetmannFibrinogen-containing dry preparation, manufacture and use thereof
US445867826 Oct 198110 Jul 1984Massachusetts Institute Of TechnologyMethod of promoting tissue generation at a wound
US447927126 Oct 198130 Oct 1984Zimmer, Inc.Tibial component for a knee joint prosthesis
US450126921 Feb 198426 Feb 1985Washington State University Research Foundation, Inc.Process for fusing bone joints
US450526617 Apr 198419 Mar 1985Massachusetts Institute Of TechnologyMethod of using a fibrous lattice
US460057421 Mar 198415 Jul 1986Immuno Aktiengesellschaft Fur Chemisch-Medizinische ProdukteMethod of producing a tissue adhesive
US460955120 Mar 19842 Sep 1986Arnold CaplanProcess of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US462785329 May 19859 Dec 1986American Hospital Supply CorporationMethod of producing prostheses for replacement of articular cartilage and prostheses so produced
US464212021 Mar 198410 Feb 1987Ramot University Authority For Applied Research And Industrial Development Ltd.Repair of cartilage and bones
US465613712 Sep 19857 Apr 1987Lescarden IncGranulating, freeze drying
US468176311 Jun 198521 Jul 1987University Of Medicine And Dentistry Of New JerseyGuanidine hydrochloride
US46831957 Feb 198628 Jul 1987Cetus CorporationOne of the first Polymerase Chain Reaction (PCR) patents
US468320225 Oct 198527 Nov 1990Cetus CorpTitle not available
US475701714 Sep 198412 Jul 1988Mcw Research Foundation, Inc.In vitro cell culture system
US477617326 Jan 198811 Oct 1988Angio-Medical CorporationMethod for extracting a substance from animal derived material
US477685327 Jul 198711 Oct 1988Hsc Research Development CorporationProcess for preparing biological mammalian implants
US47954674 Apr 19863 Jan 1989Collagen CorporationXenogeneic collagen/mineral preparations in bone repair
US480129922 Feb 198431 Jan 1989University Patents, Inc.Body implants of extracellular matrix and means and methods of making and using such implants
US48373792 Jun 19886 Jun 1989Organogenesis Inc.Fibrin-collagen tissue equivalents and methods for preparation thereof
US484683515 Jun 198711 Jul 1989Grande Daniel ATechnique for healing lesions in cartilage
US488042920 Jul 198714 Nov 1989Stone Kevin RPorous wedge-shaped matrix of collagen fibers interspersed with glycosaminoglycan molecules; for implanting in knees
US490250811 Jul 198820 Feb 1990Purdue Research FoundationTissue graft composition
US49042595 Dec 198827 Feb 1990Samuel ItayExcising damaged tissue and filling with cultured implant capable of regenerating skeletal tissue
US493297321 Apr 198812 Jun 1990El GendlerCartilage and bone induction by artificially perforated organic bone matrix
US495029613 Jun 198921 Aug 1990Mcintyre Jonathan LBone grafting units
US495048316 Dec 198821 Aug 1990Collagen CorporationImplantation, fibrils are not cross-linked
US495591120 Apr 198911 Sep 1990Sulzer Brothers LimitedBone implant
US496314620 Apr 198916 Oct 1990Colla-Tec IncorporatedMulti-layered, semi-permeable conduit for nerve regeneration
US49634898 Sep 198816 Oct 1990Marrow-Tech, Inc.Stromal support matrix
US496518817 Jun 198723 Oct 1990Cetus CorporationReacting nucleic acid with oligonucleotide primer in presence of catalytic enzyme dna polymerase; polymerase chain reaction patent
US497195423 Nov 198820 Nov 1990University Of Medicine And Dentistry Of New JerseyCollagen-based matrices ribose cross-linked
US49767382 Dec 198511 Dec 1990Sulzer Brothers LimitedPorous metal overlay for an implant surface
US49783556 Jan 198618 Dec 1990Sulzer Brothers LimitedPlastic bone implant having a reinforced contact surface
US499408423 Jun 198919 Feb 1991Brennan H GeorgeReconstructive surgery method and implant
US499455926 Jan 198919 Feb 1991Synergen, Inc.Human basic fibroblast growth factor
US500207127 Sep 198926 Mar 1991Research Development FoundationSterilized collagen material for injection in humans
US50025838 Aug 198626 Mar 1991Sandu PitaruRigid core coated with nonabsorbent polymer matrix embedded with anchored and protruding collagen fibers to bond with human or animal tissue
US50079342 Mar 198916 Apr 1991Regen CorporationProsthetic meniscus
US50325081 Sep 198916 Jul 1991Marrow-Tech, Inc.Three-dimensional cell and tissue culture system
US504113817 Apr 198920 Aug 1991Massachusetts Institute Of TechnologyNeomorphogenesis of cartilage in vivo from cell culture
US505304929 May 19851 Oct 1991Baxter InternationalFlexible prostheses of predetermined shapes and process for making same
US505305029 Apr 19881 Oct 1991Samuel ItayCells embedded in matrix
US506796321 Aug 199026 Nov 1991Washington UniversityMethod of making live autogenous skeletal replacement parts
US506796413 Dec 198926 Nov 1991Stryker CorporationArticular surface repair
US507337321 Sep 198917 Dec 1991Osteotech, Inc.Flowable demineralized bone powder composition and its use in bone repair
US50840513 Nov 198728 Jan 1992Toermaelae PerttiLayered surgical biocomposite material
US509288712 Aug 19913 Mar 1992El GendlerArtificial ligament produced from demineralized bone for the replacement and augmentation of ligaments, tendons and other fibrous connective tissue
US511851223 Jan 19902 Jun 1992Osteotech, Inc. (A Delaware Corp.)Contacting with cryopreservation and diffusion enhancing agents
US515279118 Feb 19926 Oct 1992Olympus Optical Co., Ltd.Prosthetic artificial bone having ceramic layers of different porosity
US51552148 Jan 199013 Oct 1992The Salk Institute For Biological StudiesBasic fibroblast growth factor
US519106727 Apr 19892 Mar 1993The Salk Institute For Biological StudiesFor treatment of fibroblast growth factor mediated pathophysiological conditions
US519589223 Jul 199123 Mar 1993Odontit S.A.Bone-integrated dental implant system
US520602331 Jan 199127 Apr 1993Robert F. ShawMethod and compositions for the treatment and repair of defects or lesions in cartilage
US522691416 Nov 199013 Jul 1993Caplan Arnold IMethod for treating connective tissue disorders
US523645617 Jan 199117 Aug 1993Osteotech, Inc.Osteogenic composition and implant containing same
US525614027 Mar 199226 Oct 1993Fallien Cosmeceuticals, Ltd.Composition for levelling skin
US526042024 Apr 19929 Nov 1993Centre Regional De Transfusion Sanguine De LilleConcentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US526647614 Apr 199230 Nov 1993Yeda Research & Development Co., Ltd.Fibrous matrix for in vitro cell cultivation
US52703006 Sep 199114 Dec 1993Robert Francis ShawMethods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US527582613 Nov 19924 Jan 1994Purdue Research FoundationFluidized intestinal submucosa and its use as an injectable tissue graft
US528142224 Sep 199125 Jan 1994Purdue Research FoundationFormed from intestinal tissue of mammal comprising tunica submucosa, muscularis mucosa, and stratum compactum; for connective tissue substitute
US52841556 Dec 19918 Feb 1994The General Hospital CorporationMethod for diagnosing arthritic disease
US529055827 Aug 19901 Mar 1994Osteotech, Inc.Flowable demineralized bone powder composition and its use in bone repair
US529825417 Dec 199129 Mar 1994Osteotech, Inc.Shaped, swollen demineralized bone and its use in bone repair
US530270226 Feb 199312 Apr 1994American Cyanamid CompanyChimeric fibroblast growth factors
US530630413 Jan 199326 Apr 1994El GendlerFlexible membranes produced from organic bone matrix for skeletal repair and reconstruction
US530631117 Dec 199126 Apr 1994Regen CorporationProsthetic articular cartilage
US53108834 Nov 199110 May 1994American Cyanamid CompanyStabilized versions of glu-3,5-basic FGF having eliminated disulfide scrambled forms; wound healing agents; promoters of angiogenesis, neutrotropism and chemotaxis
US531447610 Sep 199324 May 1994Osteotech, Inc.Demineralized bone particles and flowable osteogenic composition containing same
US532635718 Mar 19925 Jul 1994Mount Sinai Hospital CorporationReconstituted cartridge tissue
US532984612 Aug 199119 Jul 1994Bonutti Peter MTissue press and system
US53366162 Feb 19939 Aug 1994Lifecell CorporationMethod for processing and preserving collagen-based tissues for transplantation
US533877222 Jun 199216 Aug 1994Merck Patent Gesellschaft Mit Beschrankter HaftungImplant material
US535246313 Nov 19924 Oct 1994Badylak Steven FTissue graft for surgical reconstruction of a collagenous meniscus and method therefor
US535455718 Dec 199211 Oct 1994Stryker CorporationUnglycosylated polypeptide chains having disulfide bonding; peridontal or dental reconstruction, inducing bone formation
US535662912 Jul 199118 Oct 1994United States Surgical CorporationComposition for effecting bone repair
US536885823 Nov 199229 Nov 1994Robert F. ShawMethods and compositions for the treatment and repair of defects or lesions in cartilage
US537282115 Dec 199313 Dec 1994Purdue Research FoundationIntestinal tissue of warm-blooded vertebrate; resistance to infection; healing bone fractures
US53803289 Aug 199310 Jan 1995Timesh, Inc.Reconstructive surgery, cranial defects, layers of wire mesh and microporous membrane
US541188517 Dec 19932 May 1995New York Blood Center, Inc.Methods for tissue embedding and tissue culturing
US54257694 Mar 199320 Jun 1995Snyders, Jr.; Robert V.Composition of material for osseous repair
US543968421 Jan 19948 Aug 1995Osteotech, Inc.Shaped, swollen demineralized bone and its use in bone repair
US543981816 Dec 19858 Aug 1995Scios Nova Inc.Wound healing agents
US54439504 Oct 199322 Aug 1995Advanced Tissue Sciences, Inc.Implanting in vivo living stromal tissue prepared in vitro, comprising stromal cells with naturally secreted connective tissue proteins attached to and enveloping three-dimensional framework of biocompatible non-living material
US544583315 Dec 199329 Aug 1995Purdue Research FoundationConnective tissue substitute formed from segment of intestinal tissue of warm blooded vertebrate having multilayer end portions providing reinforcement for attachment to physiological structures and being conditioned by stretching
Non-Patent Citations
Reference
1"Young's Modulus." Entry on http://en.wikipedia.org. accessed Oct. 27, 2005. 3 pages.
2 *(No Author) "Lyophilization" TechnoBusiness-Solutions. (No publication date). Retrieved Jul. 1, 2009 from URL: ,http://www.technobusiness-solutions.com/article-lyophilization1.html> 10 pages.
3A Communication mailed Oct. 9, 2007 in connection with U.S. Appl. No. 10/438,883.
4A final Office Action mailed Dec. 28, 2009 in connection with U.S. Appl. No. 11/657,042.
5A final Office Action mailed Mar. 15, 2010 in connection with U.S. Appl. No. 10/815,778.
6A final Office Action mailed Nov. 13, 2008 in connection with U.S. Appl. No. 10/815,778.
7A final Office Action mailed Oct. 18, 2005 in connection with U.S. Appl. No. 10/438,883.
8A final Office Action mailed Sep. 19, 2008 in connection with U.S. Appl. No. 11/081,103.
9A final Office Action mailed Sep. 28, 2007 in connection with U.S. Appl. No. 10/960,960.
10Abraham, Judith A. et al., (1986) Human Basic Fibroblast Growth Factor: Nucleotide Sequence And Genomic Organization. EMBO Journal 5(10):2523-2528.
11Advisory Action mailed Dec. 27, 2007 in connection with U.S. Appl. No. 11/151,270.
12Agrawal, Sudhir et al., (1991) Pharmacokinetics. Biodistribution, And Stability Of Oligodeoxynucleotide Phosphorothioates In Mice. Proc Natl Acad Sci. USA 88(17):7595-7599.
13Andrés et al., "A Pro-Inflammatory Signature Mediates FGF2-induced Angiogenesis", Journal of Cellular and Molecular Medicine, (Jun. 28, 2008), available at http://www.ncbi.nlm.nih.gov/pubmed/18624773.
14Arakawa, Tsutomu et al., (1993) Production and Characterization of an Analog of Acidic Fibroblast Growth Factor With Enhanced Stability and Biological Activity. Protein Engineering 6(5):541-546.
15Aston et al., "Repair of Articular Surfaces by Allografts of Articular and Growth-Plate Cartilage," Journal of Bone and Joint Surgery, Jan. 1986, vol. 68-B, No. 1; pp. 29-35.
16Atala et al. (1993) Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux. J. of Urology 150(2 Pt 2):745-7.
17Aviles et al., "Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)", British Journal of Pharmacology (2003) 140: 637-646.
18Bailly, Karine et al., (2000) Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB Journal 14(2):333-343.
19Baird, "Fibroblast growth factors: activities and significance of non-neurotrophin neurotrophic growth factors", Current Opinions in Neurobiology, (1994) 4:78-86.
20Bange, Johannes et al., (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Cancer Research 62(3):840-846.
21Bork, Peer (2000) Powers and pitfalls in sequence analysis: The 70% hurdle. Genome Res. 10(4):398-400.
22Bork, Peer and Bairoch, Amnon (1996) Go hunting in sequence databases but watch out for the traps. Trends in Genetics 12(10):425-427.
23Bradford, Marion M. (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Analytical Biochemistry 72(1-2):248-254.
24Breinan et al., "Autologous Chondrocyte Implantation in a Canine Model: Change in Composition of Reparative Tissue with Time", Journal of Orthopaedic Research, 2001; 19:482-492.
25Breinan et al., "Effect of Cultured Autologous Chondrocytes on Repair of Chondral Defects in a Canine Model", Journal of Bone and Joint Surgery [Am], Oct. 1997; vol. 79-A, No. 10, 1439-1451.
26Brenner, Steven E. (1999) Errors in genome annotation. Trends in Genetics 15(4):132-133.
27Brighton et al., "Articular Cartilage Preservation and Storage-I. Application of Tissue Culture Techniques to the Storage of Viable Articular Cartilage", Arthritis and Rheumatism, vol. 22, No. 10 (Oct. 1979), pp. 1093-1101.
28Brittberg et al., "Autologous Chondrocytes Used for Articular Cartilage Repair: An Update", Clinical Orthopaedics and Related Research, 2001; No. 391 Suppl: S337-S348.
29Brittberg et al., "Rabbit Articular Cartilage Defects Treated with Autologous Cultured Chondrocytes", Clinical Orthopaedics and Related Research, 1996; 326:270-283.
30Brittberg et al., "Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation", New England Journal of Medicine, Oct. 6, 1994, vol. 331, No. 14, pp. 889-895.
31Buckwalter et al., "Articular Cartilage: Degeneration and Osteoarthritis, Repair, Regeneration, and Transplantation", AAOS Instructional Course Lectures, 1998; 47:487-504.
32Buckwalter, "Articular Cartilage Injuries", Clinical Orthopaedics and Related Research, 2002, No. 402, pp. 21-37.
33Bugbee, "Fresh Osteochondral Allografting", Operative Techniques in Sports Medicine, Apr. 2000, vol. 8, No. 2, pp. 158-162.
34Burger et al., "Fibrobblast growth factor receptor-1 is expressed by endothelial progenitor cells", Blood, vol. 100, No. 10 (Nov. 15, 2002) 3527-35.
35Bursac, "Collagen Network Contributions to Structure-Function Relationships in Cartilaginous Tissues in Compression" (Dissertation), Boston University College of Engineering, 2002.
36Cappellen, David et al., (1999) Frequent activating mutations of FGFR3 in human bladder arid cervix carcinomas. Nature Genetics 23(1):18-20.
37Carr, M. E. Jr. and Alving, B. M. (1995) Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag. Fibrinol. 6(6):567-573.
38Carr, Marcus E. (1988) Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb. Haemost. 59(3):535-539.
39Chen et al., "Repair of Articular Cartilage Defects: Part I. Basic Science of Cartilage Healing", The American Journal of Orthopedics, Jan. 1999, pp. 31-33.
40Chen et al., "Repair of Articular Cartilage Defects: Part II. Treatment Options", The American Journal of Orthopedics, Feb. 1999, pp. 88-96.
41Cheng, et al, "Chondrogenic Differentiation of Adipose-Derived Adult Stem Cells by a Porous Scaffold Derived from Native Articular Cartilage Extracellular Matrix", Tissue Engineering: Part A, vol. 15, No. 2. (2009), pp. 231-241.
42Chusho, Hideki et al., (2001) Dwarfism and early death in mice lacking C-type Natriuretic Peptide. Proc Natl Acad Sci. 98(7):4016-4021.
43Communication pursuant to Article 94(3) EPC for European Patent Application No. 08 782 728.3, dated Aug. 9, 2011.
44Cook, James L. et al., (2003) Biocompatibility of three-dimensional chondrocyte grafts in large tibial defects of rabbits. Am J Vet Res. 64(1):12-20.
45Coughlin, Shaun R. et al., (1988) Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem. 263(2):988-993.
46Crescenzi et al., "Hyaluron Linear and Crosslinked Derivatives as Potential/Actual Biomaterials", in Hyaluronan (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 261-268.
47Dahlberg et al., "Demineralized Allogeneic Bone Matrix for Cartilage Repair", Journal of Orthopaedic Research, 1991, vol. 9, pp. 11-19.
48Dell'Accio, Francesco et al., (2001) Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo, Arthritis Rheum. 44(7):1608-19.
49Diduch et al., "Joint Repair: Treatment Options for Articular Cartilage Injury" Orthopedic Technology Review (2002) 4:24-27.
50Doerks, Tobias et al., (1998) Protein annotation: detective work for function prediction. Trends Genet. 14(6):248-250.
51Dvorakova, Dana et al., (2001) Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells British Journal Haematology 13(3):832-835.
52Eriksson, A. Elisabeth et al., (1991) Three-dimensional structure of human basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88:3441-3445 (XP002936511).
53Ezzat Shereen et al., (2002) Targeted expression of A Human pituitary tumor-derived isoform of FGF Receptor-4 Recapitulates Pituitary Tumorigenesis. Journal of Clinical Investigation 109(1):69-77.
54Faham, Salem et al., (1998) Diversity does make a difference: fibroblast growth factor—Heparin interactions. Curr Opin Struct Biol 8(5):578-586.
55Feczko et al., "Experimental Results of Donor Site Filling for Autologous Osteochondral Mosaicplasty", Arthroscopy: The Journal of Arthroscopic and Related Surgery, vol. 19, No. 7 (Sep. 2003), pp. 755-761.
56Final Office Action for U.S. Appl. No. 11/081,103, mailed Aug. 11, 2010.
57Final Office Action for U.S. Appl. No. 12/381,072, mailed Jun. 27, 2011.
58Final Office Action mailed Mar. 22, 2010 in connection with U.S. Appl. No. 12/010,984.
59Final Office Action mailed Oct. 9, 2007 in connection with U.S. Appl. No. 11/151,270.
60Fingl, Edward and Woodbury, Dixon M. (1975) General Principles. In: The Pharmacological Basis of Therapeutics. Fifth edition. Goodman, Louis S. and Gilman, Alfred editors. 1:1-45.
61First Action Interview Pilot Pre-Interview Communication for U.S. Appl. No. 12/931,427, mailed Aug. 19, 2011.
62First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 12/696,366, mailed Oct. 13, 2011.
63Fujisato et al. (1996) Effect of basic fibroblast growth factor on cartilage regeneration in chondrocyte-seeded collagen sponge scaffold. Biomaterials, vol. 17, No. 2, pp. 155-162.
64Gao, Jizong et al. (2002) Repair of osteochondral defect with tissue-engineered two-phase composite material of injectable calcium phosphate and hyaluronan sponge, Tissue Engin. 13(5):827-837.
65Gargiulo, B. J. et al., (2002) Phenotypic modulation of human articular chondrocytes by bistratene A. Eur Cell Mater. 3:9-18.
66Gertzman et al., "A pilot study evaluating sodium hyaluronate as a carrier for freeze-dried demineralized bone powder", Cell and Tissue Banking, vol. 2, 2001, pp. 87-94.
67Gilbert, et al., "Decellularization of Tissues and Organs", Biomaterials (2006) 27:3675-3683.
68Girotto et al., "Tissue-specific gene expression in chondrocytes grown on three-dimensional hyaluronic acid scaffolds", Biomaterials, vol. 24 (2003), pp. 3265-3275.
69Givol, David and Yayon, Avner (1992) Complexity of FGF receptors: genetic basis for structural diversity and functional specificity FASEB J. 6(15):3362-3369.
70Glowacki, Julie, "Engineered Cartilage, Bone, Joints and Menisci-Potential for Temporomandibular Joint Reconstruction", Cells Tissues Organs, vol. 169, Issue 3, 2001, pp. 302-308.
71Gooch et al., "IGF-I and Mechanical Environment Interact to Modulate Engineered Cartilage Development", Biochemical and Biophysical Research Communications, 2001; 286:909-915.
72Gruber, Reinhard et al., (2002) Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res. 13(5):529-535.
73Guilak, Farshid; "Functional Tissue Engineering: The Role of Biomechanics in Articular Cartilage Repair", Clinical Orthopaedics and Related Research, No. 391 S, pp. S295-S305, (c) 2001 Lipponcott Williams & Wilkins, Inc., (11 pages).
74Haisch, A. et al., (2000) Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering. Med Biol Eng Comput. 38(6):686-689.
75Hecht, H. J. et al., (2000) Structure of fibroblast growth factor 9 shows a symmetric dimmer with unique receptor-and heparin-binding interfaces. Acta Cryst. D57:378-384.
76Hoffman, "Hydrogels for Biomedical Applications", Advanced Drug Delivery Reviews, 2002, vol. 43, pp. 3-12.
77http://www.stoneclinic.com/articularcartilagepastegrafting (Copyright 2009).
78http://www.technobusiness-solutions.com/article-lyophilization1.html (published Feb. 12, 2002).
79Hunziker, "Articular cartilage repair: are the intrinsic biological constraints undermining this process insuperable?", Osteoarthritis and Cartilage 7 (1999) pp. 15-28.
80Hunziker, "Articular Cartilage Repair: Basic Science and Clinical Progress. A Review of the Current Status and Prospects", Osteoarthritis and Cartilage 2001, vol. 10, No. 6, pp. 432-463.
81Hunziker, "Articular Cartilage Structure in Humans and Experimental Animals", Articular Cartilage and Osteoarthritis, Raven Press, ed., 2001, pp. 183-199.
82International Cartilage Repair Society, "Cartilage Injury Evaluation Package", www.cartilage.org, 2000.
83International Preliminary Report on Patentability for International Patent Application No. PCT/US2004/010956, issued on Nov. 18, 2005.
84International Preliminary Report on Patentability for International Patent Application No. PCT/US2004/010957, issued on Nov. 18, 2005.
85International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/008798, issued on Nov. 1, 2006.
86International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/030610, issued on Feb. 26, 2008.
87International Preliminary Report on Patentability for International Patent Application No. PCT/US2005/036878, issued on Apr. 17, 2007.
88International Preliminary Report on Patentability for International Patent Application No. PCT/US2008/051796, issued on Jul. 28, 2009.
89International Preliminary Report on Patentability for International Patent Application No. PCT/US2010/000108, mailed Jul. 28, 2011.
90International Preliminary Report on Patentability for PCT/US2009/001459, mailed on May 12, 2010.
91Itokazu, M. et al., (1997) The sustained release of antibiotic from freeze-dried fibrin-antibioticcompound and efficacies in a rat model of osteomyelitis. Infection 25(6):359-363.
92Jackson et al., "Cartilage Substitute: Overview of Basic Science & Treatment Options", Journal of American Academy of Orthopaedic Surgeons, vol. 9, Jan./Feb. 2001, pp. 37-52.
93Johnson, Daniel E. and Williams, Lewis T. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 60:1-41.
94Kato et al., "Fibroblast Growth Factor is an Inhibitor of Chondrocyte Terminal Differentiation", Journal of Biological Chemistry, vol. 265, No. 10 (Apr. 5, 1990) pp. 5903-5909.
95Kirikoshi, Hiroyuki et al., (2000) Molecular cloning and characterization of Human FGF-20 on chromosome 8p21.3-p22. Biochem Biophys Res Commun. 274(2):337-343.
96Kuroda, S. et al., (1999) Anabolic effect of aminoterminally truncated Fibroblast Growth Factor 4 (FGF4) on bone. Bone 25(4):431-437.
97Lin et al. "The Chondrocyte: Biology and Clinical Application", Tissue Engineering, vol. 12, No. 7, (2006), pp. 1971-1984.
98Loeser et al., "Basic Fibroblast Growth Factor Inhibits the Anabolic Activity of Insulin-like Growth Factor 1 and Osteogenic Protein 1 in Adult Human Articular Chondrocytes", Arthritis & Rheumatism, vol. 52, No. 12 (Dec. 2005), pp. 3910-3917.
99Lu et al., "Minced Cartilage without Cell Culture Serves as an Effective Intraoperative Cell Source for Cartilage Repair", Journal of Orthopaedic Research, Jun. 2006, vol. 24, pp. 1261-1270.
100Madry et al., "Gene Transfer of a Human Insulin-like Growth Factor I cDNA Enhances Tissue Engineering of Cartilage", Human Gene Therapy, 13: 1621-1630 (Sep. 1, 2002).
101Mahadev et al., "Autogenous Osteochondral Morselised Grafts for Full Thickness Osteochondral Defects in the Knee Joints of Pigs", Singapore Medical Journal, 2001, vol. 42(9), pp. 410-416.
102Matsuda et al. (1995) In Vivo Chondrogenesis in Collagen Sponge Sandwiched by Perichondrium. J. Biomater. Sci. Polymer Ed., vol. 7, No. 3, pp. 221-229.
103Mazué et al., "Preclinical and Clinical Studies with Recombinant Human Basic Fibroblast Growth Factor", Annals New York Academy of Sciences, (1991) 329-340.
104Messner et al., "Cartilage Repair: A Critical Review", Acta Orthopaedica Scandinavica, 1996, vol. 67, No. 5, pp. 523-529.
105Messner et al., "The Long-term Prognosis for Severe Damage to Weight-bearing Cartilage in the Knee: A 14-year Clinical and Radiographic Follow-up in 28 Young Athletes", Acta Orthopaedica Scandinavica, 1996, vol. 67, No. 2, pp. 165-168.
106Michielen et al., "Novel Biomaterials Based on Cross-linked Hyaluronon: Structural Investigations", in Hyaluronan (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 269-276.
107Nakatake, Yuhki et al., (2001) Identification of a novel fibroblast growth factor. FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim Biophys Acta. 1517(3):460-463.
108Nehrer et al., "Chondrocyte-seeded Collagen Matrices Implanted in a Chondral Defect in a Canine Model", Biomaterials, 1998; 19:2313-2328.
109Nettles et al., "In Situ Crosslinkable Hyaluronan For Articular Cartilage Repair", 50th Annual Meeting of the Orthopaedic Research Society, Paper No. 0202 (Mar. 2004).
110Nettles et al., "Photocrosslinkable Hyaluronan as a Scaffold for Articular Cartilage Repair", Annals of Biomedical Engineering, vol. 32, No. 3, Mar. 2004, pp. 391-397.
111Newman, "Articular Cartilage Repair", American Journal of Sports Medicine, 1998, vol. 26, No. 2, pp. 309-324.
112Ngo, J. Thomas et al., (1994) Computational complexity, protein structure prediction, and the Levithal Paradox. In: The Protein Folding Problem and Tertiary Structure Prediction. K. Merz Jr. and S. Le Grand, Editors. 433-506 see also table of contents.
113Nishimura, Tetsuya et al., (2000) Identification of a Novel FGF, FGF-21, Preferentially Expressed In The Liver. Biochim Biophys Acta 1492(1):203-206.
114Nixon et al., "Enhanced Repair of Extensive Articular Defects by Insulin-like Growth Factor-I-Laden Fibrin Composites", Journal of Orthopaedic Research, 1999; 17:475-487.
115Nixon et al., "New Horizons in Articular Cartilage Repair", Proceedings of the Annual Convention of the AAEP, 2001, vol. 47, pp. 217-226.
116Nolan et al., "Living Bone Grafts", BMJ, vol. 304, Jun. 13, 1992, pp. 1520 and 1521.
117Non-final Office Action for U.S. Appl. No, 12/924,132, mailed Jul. 18, 2011.
118Non-final Office Action for U.S. Appl. No. 11/081,103, mailed Nov. 28, 2011.
119Non-Final Office Action for U.S. Appl. No. 12/010,984, mailed Aug. 16, 2010.
120Non-final Office Action for U.S. Appl. No. 12/043,001, mailed May 11, 2011.
121Non-final Office Action for U.S. Appl. No. 12/179,034, mailed Jun. 29, 2011.
122Non-final Office Action for U.S. Appl. No. 12/322,996, mailed Apr. 4, 2011.
123Non-final Office Action for U.S. Appl. No. 12/508,892, mailed Dec. 7, 2011.
124Non-final Office Action for U.S. Appl. No. 12/881,988, mailed Oct. 26, 2011.
125Non-Final Office Action mailed Apr. 12, 2010 in connection with U.S. Appl. No. 12/191,490.
126Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 11/657,042.
127Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 12/079,629.
128Non-final Office Action mailed Apr. 19, 2007 in connection with U.S. Appl. No. 11/151,270.
129Non-Final Office Action mailed Apr. 26, 2010 in connection with U.S. Appl. No. 12/147,042.
130Non-final Office Action mailed Aug. 19, 2009 in connection with U.S. Appl. No. 12/147,042.
131Non-final Office Action mailed Dec. 18, 2007 in connection with U.S. Appl. No. 11/081,103.
132Non-final Office Action mailed Feb. 20, 2007 in connection with U.S. Appl. No. 10/960,960.
133Non-final Office Action mailed Feb. 6, 2007 in connection with U.S. Appl. No. 10/438,883.
134Non-final Office Action mailed Feb. 7, 2008 in connection with U.S. Appl. No. 10/815,778.
135Non-final Office Action mailed Jan. 14, 2010 in connection with U.S. Appl. No. 11/081,103.
136Non-final Office Action mailed Jul. 2, 2009 in connection with U.S. Appl. No. 10/815,778.
137Non-final Office Action mailed Jul. 22, 2009 in connection with U.S. Appl. No. 12/010,984.
138Non-final Office Action mailed Jul. 9, 2008 in connection with U.S. Appl. No. 11/151,270.
139Non-final Office Action mailed Jun. 3, 2009 in connection with U.S. Appl. No. 11/081,103.
140Non-final Office Action mailed May 18, 2009 in connection with U.S. Appl. No. 11/657,042.
141Non-final Office Action mailed May 3, 2005 in connection with U.S. Appl. No. 10/438,883.
142Non-final Office Action mailed Nov. 12, 2008 in connection with U.S. Appl. No. 10/438,883.
143Non-final Office Action mailed Nov. 5, 2004 in connection with U.S. Appl. No. 10/438,883.
144Non-final Office Action mailed Oct. 5, 2005 in connection with U.S. Appl. No. 10/424,765.
145Non-final Office Action with regard to U.S. Appl. No. 12/381,072, mailed Jan. 20, 2011.
146Non-final Office Action with regard to U.S. Appl. No. 12/924,132, mailed Mar. 1, 2011.
147Obradovic et al., "Integration of Engineered Cartilage", Journal of Orthopaedic Research, 19:1089-1097, 2001.
148Okada-Ban, Mai et al., (2000) Fibroblast growth factor-2. International Journal of Biochemistry & Cell Biology 32 (3):263-267.
149Olsen, Shaun K. (2003) Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem. 278(36):34226-342236.
150Ornitz et al., "Protein Family Review: Fibroblast Growth Factors", Genome Biology (2001) 2(3): reviews 3005.1-3005.12, available at http://genomebiology.com/2001/2/3/reviews/3005.1.
151Ornitz, David M. (2000) FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bio Essays 22:108-112.
152Ornitz, David M. et al., (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271(25)1 5292-7.
153OsteoSponge product information, Bacterin International Inc., May 2005.
154Pearson et al. (eds.), American Association of Tissue Banks, Standards for Tissue Banking, 2008 (12th ed.), pp. 53-56, 86-88.
155Pei et al., "Bioreactors Mediate the Effectiveness of Tissue Engineering Scaffolds", The FASEB Journal, 16:1691-1694, published online (Aug. 7, 2002), 10.1096/fj.02-0083fje.
156Pei et al., "Growth Factors for Sequential Cellular De- and Re-differentiation in Tissue Engineering", Biochemical and Biophysical Research Communications, 2002; 294:149-154.
157Pellegrini, Luca et al., (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407(6807):1029-1034.
158Peretti et al., "A Biomedical Analysis of an Engineered Cell-Scaffold Implant for Cartilage Repair", Annals of Plastic Surgery, 2001, vol. 46, No. 5, pp. 533-537.
159Peretti et al., "Biomechanical Analysis of a Chondrocyte-Based Repair Model of Articular Cartilage", Tissue Engineering, Aug. 1, 1999, vol. 5. No. 4, pp. 317-326.
160Peretti et al., "Cell-Based Bonding of Articular Cartilage: An Extended Study", Journal of Biomedical Materials Research, 64A, 2003, pp. 517-524.
161Peretti et al., "Cell-based Tissue-Engineered Allogeneic Implant for Cartilage Repair" Tissue Engineering, 2000, vol. 6. No. 5, pp. 567-576.
162Peretti et al., "In Vitro Bonding of Pre-seeded Chondrocyte", Sport Sciences for Health, May 1, 2007, vol. 2, No. 1, pp. 29-33.
163Peretti et al., "Bonding of Cartilage Matrices with Cultured Chondrocytes: An Experiential Model", Journal of Orthopedic Research, Jan. 1998, vol. 16, No. 1, pp. 89-95.
164Peterson et al., "Autologous Chondrocyte Transplantation: Biomechanics and Long-term Durability", American Journal of Sports Medicine, 2002, vol. 30, No. 1, pp. 2-12.
165Peterson et al., "Two- to 9-year Outcome After Autologous Chondrocyte Transplantation of the Knee", Clinical Orthopaedics and Related Research, 2000; No. 374: 212-234.
166Pillai, Omathanu and Panchagnula, Ramesh (2001) Polymers in drug delivery. Curr Opin Chem Biol 5 (4):447-451.
167Plotnikov, Alexander N. et al., (1999) Structural basis for FGF receptor dimerization and activation. Cell 98 (5):641-650.
168Plotnikov, Alexander N. et al., (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101(4): 413-424.
169Richardson et al., "Repair of Human Articular Cartilage After Implantation of Autologous Chondrocytes", Journal of Bone and Joint Surgery [Br], 1999; 81-B:1064-1068.
170Sahni, Malika et al., (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway Genes Deve1.13(11):1361-1366.
171Schaefer et al., "Tissue Engineered Composites for the Repair of Large Osteochondral Defects", Arthritis & Rheumatism, 46(9): 2524-2534 (2002).
172Schlessinger, Joseph et al., (2000) Crystal structure of a ternary FGF-FGFR-1 Heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6(3):743-750.
173Schmal, H. et al., (2007) bFGF influences human articular chondrocyte differentiation. Cytotherapy 9(2):184-93.
174Search Report and Written Opinion for International Patent Application No. PCT/US2004/010957, issued on Nov. 1, 2004.
175Search Report and Written Opinion for International Patent Application No. PCT/US2005/008798, issued on Jun. 19, 2006.
176Search Report and Written Opinion for International Patent Application No. PCT/US2005/030610, issued on Apr. 7, 2006.
177Search Report and Written Opinion for International Patent Application No. PCT/US2005/036878, issued on Sep. 21, 2006.
178Search Report and Written Opinion for International Patent Application No. PCT/US2005/051796, issued on Jun. 23, 2009.
179Search Report and Written Opinion for International Patent Application No. PCT/US2008/085522, issued on Jul. 6, 2009.
180Search Report and Written Opinion for International Patent Application No. PCT/US2009/001459, issued on Jul. 6, 2009.
181Search Report and Written Opinion for International Patent Application No. PCT/US2010/085522, issued Jan. 14, 2010.
182Search Report andf Written Opinion for International Patent Application No. PCT/US2004/010956, issued on Oct. 28, 2005.
183Sedgwick et al., "Studies into the influence of carrageenan-induced inflammation on articular cartilage degradation using implantation into air pouches", British Journal of Experimental Pathology, vol. 66, (1985), pp. 445-453.
184Seno, Masaharu et al., (1990) Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for Heparin. Eur J Biochem. 188:239-245.
185Shao, Zhang-Qiang et al., (2006) Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodeling in a rat infarct model. Circ. J. 70(4):471-477.
186Sims, C. Derek et al., (1998) Tissue engineered neocartilage using plasma derived polymer substrates and chondrocytes. Plastic & Recon. Surg. 101(6):1580-1585.
187Skolnik, Jeffrey and Fetrow, Jacquelyn S. (2000) From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends BioTechnol. 18(1):34-39.
188Sleeman, Matthew et al., (2001) Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271 (2):171-182.
189Smith, Temple and Zhang, Xiaolin (1997) The challenges of genome sequence annotation or The devil is in the details. Nat Biotechnol. 15(12):1222-1223.
190Spangenberg, Kimberly, M., et al. "Histomorphometric Analysis of a Cell-Based Model of Cartilage Repair", Tissue Engineering, vol. 8, No. 5, 2002, (8 pages).
191Springer, Barry A. et al., (1994) Identification and Concerted Function of Two Receptors Binding Surfaces on Basic Fibroblast Growth Factor Required for Mitogenesis. The Journal of Biological Chemistry 269(43):26879-26884.
192Stauber, Deborah J. et al., (2000) Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci USA 97(1):49-54.
193Stone et al., "Articular Cartilage Paste Grafting to Full-Thickness Articular Cartilage Knee Joint Lesions: A 2- to 12-Year Follow-up", Arthroscopy: The Journal of Arthoscopic and Related Surgery, Mar. 2006, vol. 22, No. 3, pp. 291-299.
194Stone et al., "One-Step American Technique of Articular Cartilage Paste Grafting to Traumatic and Arthritic Defects in the Knee Joint (2-7 Years Follow-Up)", downloaded from http:web.archive.org/web/20041205005845/http://www.stoneclinic.com/onestep.thm; published Dec. 5, 2004.
195Supplemental Search report for European Patent Application No. 05728956.3, dated May 2, 2011.
196Temenoff et al., "Review: Tissue engineering for regeneration of articular cartilage", Biomaterials 21 (2000) pp. 431-440.
197Trzeciak et al., "Evaluation of Cartilage Reconstruction by Means of Autologous Chondrocyte Versus Periosteal Graft Transplantation: An Animal Study", Transplantation Proceedings, vol. 38 (2006), pp. 305-311.
198Tsumaki et al. "Role of CDMP-1 in Skeletal Morphogenesis: Promotion of Mesenchymal Cell Recruitment and Chondrocyte Differentiation", J. Cell Biol., Jan. 1999, vol. 144, No. 1, 161-173.
199U.S. Appl. No. 12/147,042, based on U.S. Patent No. 7,067,123, filed Jun. 26, 2008, entitled: "Novel Glue for Cartilage Repair".
200U.S. Appl. No. 12/881,988, filed Sep. 14, 2010.
201U.S. Appl. No. 12/924,132, filed Sep. 21, 2010.
202U.S. Appl. No. 13/025,722, filed Feb. 11, 2011.
203Umlauf et al., "Cartilage biology, pathology, and repair", Cell. Mol. Life Sci., vol. 67, (2010), pp. 4197-4211.
204Vajo, Zoltan et al., (2000) The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans. Endocrine Rev. 21(1):23-39.
205Verbruggen et al., "Repair Function in Organ Cultured Human Cartilage. Replacement of Enzymatically Removed Proteoglycans During Longterm Organ Culture", The Journal of Rheumatology, 12:4, (1985), pp. 665-674.
206Vunjak-Novakovic et al., "Bioreactor Cultivation Conditions Modulate the Composition and Mechanical Properties of Tissue-Engineered Cartilage", Journal of Orthopaedic Research, 1999; 17:130-138.
207Wells, James A. (1990) Additivity of mutational effects in proteins. Biochemistry 29(37):8509-8517.
208Yamashita, Tetsuo et al., (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and Biophysical Research Communications 277(2):494-498.
209Yayon, Avner et al., (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64(4):841-848.
210Yee, Cindy J. et al., (2000) Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. Journal of the National Cancer Institute 92(22):1848-1849.
211Zhang, Jiandong et al., (1991) Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 Beta. Proc Natl Acad Sci. USA 88(8):3446-3450.
212Zhu, Hengyi et al., (1995) Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. Journal Of Biological Chemistry 270(37):21869-21874.
213Zhu, Hengyi et al., (1997) Analysis of high-affinity binding determinants in the receptor binding epitope of basic fibroblast growth factor. Protein Engineering 10(4):417-421.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US868543223 Mar 20091 Apr 2014University Of Utah Research FoundationControlled release tissue graft combination biomaterials
Classifications
U.S. Classification424/548, 424/93.7
International ClassificationA61K35/32
Legal Events
DateCodeEventDescription
27 Nov 2013FPAYFee payment
Year of fee payment: 8
8 Dec 2011ASAssignment
Owner name: MUSCULOSKELETAL TRANSPLANT FOUNDATION, NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOMES, KATHERINE A.;SUNWOO, MOON HAE;GERTZMAN, ARTHUR A.;AND OTHERS;SIGNING DATES FROM 20040224 TO 20040317;REEL/FRAME:027346/0817